NCT00179725View on ClinicalTrials.gov

Phase I/II Open-Label, Dose Escalation Study To Determine The Maximum Tolerated Dose And To Evaluate The Safety Profile of Lenalidomide (Revlimid® CC-5013) With Liposomal Doxorubicin In Subjects With Advanced Ovarian and Primary Peritoneal Carcinoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 30, 2005

Study Completion Date

June 30, 2007

Conditions
Ovarian Cancer
Interventions
DRUG

CC-5013

DRUG

liposomal doxorubicin

Trial Locations (5)

10021

Memorial Sloan-Kettering Cancer Center, New York

32806

MD Anderson Cancer Center Orlando, Orlando

73104

OU Health Sciences Center, Oklahoma City

94115

University of California at San Francisco, San Francisco

98104

Swedish Cancer Institute, Seattle

Sponsors
All Listed Sponsors
collaborator

Prologue Research International

INDUSTRY

lead

Celgene Corporation

INDUSTRY